Menu
Search
|

Menu

Close
X

Oramed Pharmaceuticals Inc ORMP.OQ (NASDAQ Stock Exchange Capital Market)

7.40 USD
+0.03 (+0.41%)
As of Feb 23
chart
Previous Close 7.37
Open 7.36
Volume 1,171
3m Avg Volume 8,922
Today’s High 7.42
Today’s Low 7.36
52 Week High 11.34
52 Week Low 5.85
Shares Outstanding (mil) 14.37
Market Capitalization (mil) 106.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
1
FY15
0
EPS (USD)
FY18
-0.178
FY17
-0.787
FY16
-0.864
FY15
-0.669
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
43.28
8.35
Price to Book (MRQ)
vs sector
4.66
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-27.08
13.63
Return on Equity (TTM)
vs sector
-44.41
15.39

EXECUTIVE LEADERSHIP

Kevin Rakin
Chairman of the Board, Independent Director, Since 2016
Salary: --
Bonus: --
Nadav Kidron
President, Chief Executive Officer, Director, Since 2006
Salary: $273,086.00
Bonus: $195,729.00
Hilla Eisenberg
Chief Financial Officer, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Joshua Hexter
Chief Operating Officer, Vice President - Business Development, Since 2013
Salary: $132,306.00
Bonus: $86,974.00
Miriam Kidron
Chief Scientific Officer, Director, Since 2006
Salary: $203,378.00
Bonus: $136,583.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Hi-Tech Park 2 4 Givat Ram,
PO Box 39098
JERUSALEM     91390

Phone: +9722.5660001
Site: oramed.com

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

SPONSORED STORIES